Centessa Pharmaceuticals plc (CNTA)
| Market Cap | 6.13B +237.9% |
| Revenue (ttm) | n/a |
| Net Income | -250.64M |
| EPS | -1.78 |
| Shares Out | 154.73M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 682,256 |
| Open | 39.66 |
| Previous Close | 39.61 |
| Day's Range | 39.53 - 39.75 |
| 52-Week Range | 10.95 - 40.26 |
| Beta | 1.14 |
| Analysts | Buy |
| Price Target | 43.17 (+9.03%) |
| Earnings Date | Aug 4, 2026 |
About CNTA
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia. It also engages in the development of ORX142 which is in Phase I clinical trial for the treatment of neurological and neurodegenerative disorders... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for CNTA stock is "Buy." The 12-month stock price target is $43.17, which is an increase of 9.03% from the latest price.
News
Centessa downgraded to Equal Weight from Overweight at Wells Fargo
Wells Fargo downgraded Centessa (CNTA) to Equal Weight from Overweight with a $42 price target after after Eli Lilly (LLY) announced an agreement to acquire the company for $38 per
Centessa downgraded to Hold from Buy at Truist
Truist analyst Danielle Brill downgraded Centessa (CNTA) to Hold from Buy with a $38 price target after Eli Lilly (LLY) announced an agreement to acquire the company for $38 per
Centessa downgraded to Neutral from Buy at Guggenheim
Guggenheim analyst Debjit Chattopadhyay downgraded Centessa (CNTA) to Neutral from Buy after Eli Lilly (LLY) announced an agreement to acquire the company for $38 per share in cash plus a
Centessa downgraded to Market Perform from Outperform at LifeSci Capital
LifeSci Capital downgraded Centessa (CNTA) to Market Perform from Outperform after Eli Lilly (LLY) announced an agreement to acquire the company for $38 per share in cash plus a non-transferable
Centessa downgraded to Market Perform from Outperform at Leerink
Leerink downgraded Centessa (CNTA) to Market Perform from Outperform with a $40 price target after Eli Lilly (LLY) announced an agreement to acquire the company for $38 per share in
Nxera Pharma's Partner Centessa Pharmaceuticals to be Acquired by Lilly
Tokyo, Japan and Cambridge, UK, 1 April 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that its partner, Centessa Pharmaceuticals Limited (“Centessa”), has announced that...
Alkermes jumps 15% on renewed biotech M&A buzz, says Leerink
Alkermes (ALKS) rose 15% after Eli Lilly (LLY) agreed to acquire Centessa Pharmaceuticals (CNTA), reflecting renewed M&A momentum in biotech, Leerink tells investors in a research note. While the boos...
Centessa acquisition ‘may help rouse’ Alkermes shares, says RBC Capital
After Eli Lilly (LLY) announced the intent to acquire Centessa (CNTA) for $6.3B in cash plus an additional $1.5B split across 3 contingent value rights, RBC Capital said the deal
Eli Lilly stock rises after $7.8B Centessa deal—bet on sleep drugs
Eli Lilly has agreed to acquire Centessa Pharmaceuticals in a deal valued at up to $7.8 billion, marking a significant expansion of the drugmaker's neuroscience portfolio into sleep medicine. Under th...
Alkermes jumps after Eli Lilly acquires peer Centessa
Shares of Alkermes (ALKS) ALKS) are moving higher after Eli Lilly (LLY) reached an agreement to acquire Centessa (CNTA) for up to $7.8B. Alkermes, like Centessa, is developing an orexin
Centessa downgraded to Peer Perform from Outperform at Wolfe Research
Wolfe Research downgraded Centessa (CNTA) to Peer Perform from Outperform following the announcement of Eli Lilly’s (LLY) acquisition agreement. The firm believes Centessa has a “very good chance to h...
Lilly to spend up to $7.8 billion to acquire Centessa, a maker of experimental sleep disorder drugs
Eli Lilly will pay up to $7.8 billion to acquire Centessa Pharmaceuticals. Centessa is developing orexin agonists to treat narcolepsy and excessive drowsiness.
Centessa downgraded to Neutral from Buy at B. Riley
B. Riley analyst Mayank Mamtani downgraded Centessa (CNTA) to Neutral from Buy with a $45 price target after Eli Lilly (LLY) announced an agreement to acquire the company for $38
Why Eli Lilly Is Buying Centessa for $7.8 Billion
Bloomberg Intelligence's Sam Fazeli discusses Eli Lilly's $7.8 billion acquisition of Centessa, marking the company's entry into the sleep disorder drug market. He speaks on "Bloomberg Open Interest.
Centessa downgraded to Hold from Buy at Needham
Needham downgraded Centessa (CNTA) to Hold from Buy after Eli Lilly (LLY) agreed to acquire all of the issued and to be issued share capital of Centessa for $38.00 in
Eli Lilly to Buy Centessa Pharmaceuticals for Initial $6.3 Billion
Eli Lilly has agreed to buy clinical-stage company Centessa Pharmaceuticals for an initial $6.3 billion in a deal that expands the drugmaker's neuroscience portfolio and capabilities into sleep medici...
Eli Lilly to buy Centessa Pharma in $6.3 billion deal
Eli Lilly said on Tuesday it would buy Centessa Pharmaceuticals in a deal worth about $6.3 billion to advance treatments for sleep-wake disorders.
Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
Centessa's OX2R agonist pipeline includes a potential best-in-class therapeutic with significant promise to meaningfully improve outcomes across a range of sleep-wake disorders Acquisition expands Lil...
Centessa Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026
The CEO outlined a vision to lead in rare hypersomnias with a best-in-class orexin-2 agonist, supported by strong early efficacy data and a flexible, adaptive clinical strategy. Plans include expanding into broader neuroscience indications and building a commercial team.
Nxera Pharma to Receive US$3 Million Milestone Payment from Centessa Pharmaceuticals
Tokyo, Japan and Cambridge, UK, 5 March 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that Centessa Pharmaceuticals has achieved an additional early development mi...
Centessa Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference
ORX750 has shown strong efficacy and tolerability in early studies, with registrational trials for rare hypersomnias set to begin this quarter. The platform is expanding into additional neuropsychiatric and neurodegenerative indications, supported by a robust commercial and educational strategy.
Centessa Pharmaceuticals Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
The company is advancing orexin agonists for rare hypersomnias, with plans to start registrational studies this quarter and expand into broader neuroscience indications. ORX750 has shown best-in-class efficacy, and next-gen assets are entering the clinic to address additional CNS disorders.
Nxera Pharma to Receive $1.8 Million Milestone Payment from Centessa Pharmaceuticals
Tokyo, Japan and Cambridge, UK, 12 February 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today notes that Centessa Pharmaceuticals has achieved an early development milestone ass...